Stifel analyst Mathew Blackman downgraded Apollo Endosurgery (APEN) to Hold from Buy with a $10 price target after Boston Scientific (BSX) announced a deal to acquire the company for $10 per share in cash back in November. Citing the recent merger proxy, two other parties expressed interest in Apollo, but neither party made a bid, and at this point, it is unlikely that alternative offers emerge, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APEN:
- Apollo Endosurgery announces two milestones for endoscopic systems
- Apollo Endosurgery advances endoscopic procedures for obese patients
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – VVNT, SAL, GRAY, APEN
- Apollo Endosurgery downgraded to Hold from Buy at Lake Street
- Piper says Apollo Endosurgery can help Boston Scientific expand ELS franchise